Posted inBiotechnology
Salicylic Acid Affects Strawberry Yield and Quality
In a groundbreaking study published in Scientific Reports, researchers Khajeh Sorkhoeih, Hamidi Moghaddam, and Seyedi delve deep into the effects…
Posted inBiotechnology
Bidirectional CRISPR Maps GLIS3 Fibrosis Circuit
A groundbreaking study reveals the pivotal role of the transcription factor GLIS3 in orchestrating a fibrotic cell circuit linked to…
Posted inBiotechnology
Giant Infrared Nonlinear Optical Effect in 2D Mott Insulator
In a groundbreaking study pushing the frontiers of nonlinear optics and two-dimensional (2D) materials science, researchers have unveiled an extraordinary…
Posted inBiotechnology
Unveiling Intersectional Biases in AI-Generated Narratives
In recent years, generative language models have revolutionized how we interact with artificial intelligence, enabling machines to produce coherent, creative,…
Posted inBiotechnology
J&J, Google venture arms line up to back protein degradation biotech EpiBiologics’ $107M series B
Protein degradation biotech EpiBiologics has brought in $107 million in a star-studded series B round headed up by Johnson &…
Posted inBiotechnology
Assessing Inertial Measurement Systems for Hockey Biomechanics
In the realm of sports engineering, an innovative study has emerged, casting a spotlight on the quantification of biomechanical joint…
Posted inBiotechnology
Rethinking Arsenic Cleanup in Farm Soils
In a groundbreaking review that challenges longstanding assumptions about soil remediation, scientists are turning their focus to the biovolatilization and…
Posted inMedical Technology
Lexeo Therapeutics, J&J team up to test heart pump technology for cardiac gene therapy delivery
Lexeo Therapeutics is teaming up with Big Pharma Johnson & Johnson's unit Abiomed to tap its Impella heart pump technology…
Posted inBiotechnology
Foresee offloads MMP-12 inhibitors in $584M deal, focuses on Camcevi’s potential
Foresee Pharmaceuticals has sold a chunk of its clinical-stage pipeline in order to focus on the potential of its prostate…
Posted inBiotechnology
Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution
Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to 64% overall survival (OS)…